Gilead Sciences is expected to report Q1 2026 revenue of $6.89 billion and EPS of $1.89, with its current stock price of $132.69 trading roughly 16% below the consensus analyst price target of $158.86. Investors are primarily focused on the continued dominance of the HIV franchise, specifically the sales performance of Biktarvy and the market uptake of the recently launched twice-yearly injectable lenacapavir.
The company's base business has shown resilient 4% growth in recent periods, though results may be tempered by competitive headwinds in the cell therapy segment and rising R&D expenditures. Management's updated guidance on the oncology portfolio, led by Trodelvy, remains a critical secondary focus as Gilead shifts its strategic weight toward higher-growth therapeutic areas.